Glucose addiction in cancer therapy: Advances and drawbacks

Current Drug Metabolism

Volumn 16, Issue 3, 2015, Pages 221-242

  Granja, Sara ^a,b   Pinheiro, Céline ^a,b,c,d   Reis, Rui Manuel ^a,b,d   Martinho, Olga ^a,b   Baltazar, Fátima ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Barretos School of Health Sciences   (Brazil)

^d BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Cancer metabolism; Drug resistance; Glucose; Targeted therapy; Warburg effect

Indexed keywords

3 BROMOPYRUVATE; 6 PHOSPHOFRUCTO 2 KINASE FRUCTOSE 2,6 ISPHOSPHATASE 3; ANGIOGENESIS INHIBITOR; AZD 3965; B RAF KINASE INHIBITOR; BCR ABL PROTEIN; BIGUANIDE DERIVATIVE; DEOXYGLUCOSE; DICHLOROACETIC ACID; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GOSSYPOL; HEXOKINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LACTATE DEHYDROGENASE; LACTIC ACID; LONIDAMINE; MONOCARBOXYLATE TRANSPORTER; OXIDOREDUCTASE INHIBITOR; PHLORETIN; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE KINASE ISOZYME M2; SILIBININ; STF 31; TLN 232; UNCLASSIFIED DRUG; WZB 117; ANTINEOPLASTIC AGENT; GLUCOSE TRANSPORTER;

ARTICLE; CANCER CELL; CANCER THERAPY; CELL GROWTH; CHEMOTHERAPY; DRUG TARGETING; ENERGY METABOLISM; GLUCOSE INTAKE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; METABOLIC ACIDOSIS; ONCOGENE; TREATMENT RESPONSE; AEROBIC METABOLISM; DRUG EFFECTS; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AEROBIOSIS; ANTINEOPLASTIC AGENTS; ENERGY METABOLISM; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLYCOLYSIS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84940833346     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666150602145145     Document Type: Article

References (264)

1. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5), 646-74.
2. Warburg, O. On the origin of cancer cells. Science, 1956, 123(3191), 309-14.
3. Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4(11), 891-9.
4. Pelicano, H.; Martin, D. S.; Xu, R. H.; Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene, 2006, 25(34), 4633-46.
5. Chen, Z.; Lu, W.; Garcia-Prieto, C.; Huang, P. The Warburg effect and its cancer therapeutic implications. J. Bioenerg. Biomembr., 2007, 39(3), 267-74.
6. Cuezva, J. M.; Krajewska, M.; de Heredia, M. L.; Krajewski, S.; Santamaria, G.; Kim, H.; Zapata, J. M.; Marusawa, H.; Chamorro, M.; Reed, J. C. The bioenergetic signature of cancer: A marker of tumor progression. Cancer Res., 2002, 62(22), 6674-81.
7. Isidoro, A.; Martinez, M.; Fernandez, P. L.; Ortega, A. D.; Santamaria, G.; Chamorro, M.; Reed, J. C.; Cuezva, J. M. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem. J., 2004, 378(Pt 1), 17-20.
8. Matoba, S.; Kang, J. G.; Patino, W. D.; Wragg, A.; Boehm, M.; Gavrilova, O.; Hurley, P. J.; Bunz, F.; Hwang, P. M. p53 regulates mitochondrial respiration. Science, 2006, 312(5780), 1650-3.
9. Bui, T. and Thompson, C. B. Cancer's sweet tooth. Cancer Cell, 2006, 9(6), 419-20.
10. Vander Heiden, M. G.; Plas, D. R.; Rathmell, J. C. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol. Cell. Biol., 2001, 21(17), 5899-912.
11. Ran, C.; Liu, H.; Hitoshi, Y. Proliferation-independent control of tumor glycolysis by PDGFR-mediated AKT activation. Cancer Res., 2013, 73(6), 1831-43.
12. Deberardinis, R. J.; Sayed, N.; Ditsworth, D. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev., 2008, 18(1), 54-61.
13. Szablewski, L. Expression of glucose transporters in cancers. Biochim. Biophys. Acta, 2013, 1835(2), 164-9.
14. Van den Abbeele, A. D.; Badawi, R. D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer, 2002, 38 Suppl 5, S60-5.
15. Hughes, B.; Yip, D.; Goldstein, D.; Waring, P.; Beshay, V.; Chong, G. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer, 2004, 4, 74.
16. Breccia, M.; Muscaritoli, M.; Aversa, Z.; Mandelli, F.; Alimena, G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J. Clin. Oncol., 2004, 22(22), 4653-5.
17. Breccia, M.; Muscaritoli, M.; Cannella, L.; Stefanizzi, C.; Frustaci, A.; Alimena, G. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk. Res., 2008, 32(10), 1626-8.
18. McArthur, G. A.; Puzanov, I.; Amaravadi, R.; Ribas, A.; Chapman, P.; Kim, K. B.; Sosman, J. A.; Lee, R. J.; Nolop, K.; Flaherty, K. T.; Callahan, J.; Hicks, R. J. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J. Clin. Oncol., 2012, 30(14), 1628-34.
19. Baudy, A. R.; Dogan, T.; Flores-Mercado, J. E.; Hoeflich, K. P.; Su, F.; van Bruggen, N.; Williams, S. P. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res., 2012, 2(1), 22.
20. Grimpen, F.; Yip, D.; McArthur, G.; Waring, P.; Goldstein, D.; Loughrey, M.; Beshay, V.; Chong, G. Resistance to imatinib, lowgrade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol., 2005, 6(9), 724-7.
21. Yun, J.; Rago, C.; Cheong, I.; Pagliarini, R.; Angenendt, P.; Rajagopalan, H.; Schmidt, K.; Willson, J. K.; Markowitz, S.; Zhou, S.; Diaz, L. A. Jr.; Velculescu, V. E.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B.; Papadopoulos, N. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science, 2009, 325(5947), 1555-9.
22. Bhattacharya, B.; Low, S. H.; Soh, C.; Kamal Mustapa, N.; Beloueche- Babari, M.; Koh, K. X.; Loh, J.; Soong, R. Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype. Br. J. Pharmacol., 2014, 171(13), 3255-67.
23. Elstrom, R. L.; Bauer, D. E.; Buzzai, M.; Karnauskas, R.; Harris, M. H.; Plas, D. R.; Zhuang, H.; Cinalli, R. M.; Alavi, A.; Rudin, C. M.; Thompson, C. B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res., 2004, 64(11), 3892-9.
24. Luo, Y.; Yang, C.; Ye, M.; Jin, C.; Abbruzzese, J. L.; Lee, M. H.; Yeung, S. C.; McKeehan, W. L. Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. Cancer Metab., 2013, 1(1), 21.
25. Shimura, T.; Noma, N.; Sano, Y.; Ochiai, Y.; Oikawa, T.; Fukumoto, M.; Kunugita, N. AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells. Radiother. Oncol., 2014.
26. Park, S. Y.; Kim, E. J.; Shin, H. K.; Kwon, D. Y.; Kim, M. S.; Surh, Y. J.; Park, J. H. Induction of apoptosis in HT-29 colon cancer cells by phloretin. J. Med. Food, 2007, 10(4), 581-6.
27. Wu, C. H.; Ho, Y. S.; Tsai, C. Y.; Wang, Y. J.; Tseng, H.; Wei, P. L.; Lee, C. H.; Liu, R. S.; Lin, S. Y. In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. Int. J. Cancer, 2009, 124(9), 2210-9.
28. Kobori, M.; Iwashita, K.; Shinmoto, H.; Tsushida, T. Phloretininduced apoptosis in B16 melanoma 4A5 cells and HL60 human leukemia cells. Biosci. Biotechnol. Biochem., 1999, 63(4), 719-25.
29. Kobori, M.; Shinmoto, H.; Tsushida, T.; Shinohara, K. Phloretininduced apoptosis in B16 melanoma 4A5 cells by inhibition of glucose transmembrane transport. Cancer Lett., 1997, 119(2), 207-12.
30. Nelson, J. A.; Falk, R. E. The efficacy of phloridzin and phloretin on tumor cell growth. Anticancer Res., 1993, 13(6A), 2287-92.
31. Pajor, A. M.; Randolph, K. M.; Kerner, S. A.; Smith, C. D. Inhibitor binding in the human renal low- And high-affinity Na+/glucose cotransporters. J. Pharmacol. Exp. Ther., 2008, 324(3), 985-91.
32. Cao, X.; Fang, L.; Gibbs, S.; Huang, Y.; Dai, Z.; Wen, P.; Zheng, X.; Sadee, W.; Sun, D. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother. Pharmacol., 2007, 59(4), 495-505.
33. Yang, K. C.; Tsai, C. Y.; Wang, Y. J.; Wei, P. L.; Lee, C. H.; Chen, J. H.; Wu, C. H.; Ho, Y. S. Apple polyphenol phloretin potentiates the anticancer actions of paclitaxel through induction of apoptosis in human hep G2 cells. Mol. Carcinog., 2009, 48(5), 420-31.
34. Zhu, S. P.; Liu, G.; Wu, X. T.; Chen, F. X.; Liu, J. Q.; Zhou, Z. H.; Zhang, J. F.; Fei, S. J. The effect of phloretin on human gammadelta T cells killing colon cancer SW-1116 cells. Int. Immunopharmacol., 2013, 15(1), 6-14.
35. Zhan, T.; Digel, M.; Kuch, E. M.; Stremmel, W.; Fullekrug, J. Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J. Cell. Biochem., 2011, 112(3), 849-59.
36. Deep, G.; Agarwal, R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev., 2010, 29(3), 447-63.
37. Flaig, T. W.; Glode, M.; Gustafson, D.; van Bokhoven, A.; Tao, Y.; Wilson, S.; Su, L. J.; Li, Y.; Harrison, G.; Agarwal, R.; Crawford, E. D.; Lucia, M. S.; Pollak, M. A study of high-dose oral silybinphytosome followed by prostatectomy in patients with localized prostate cancer. Prostate, 2010, 70(8), 848-55.
38. Flaig, T. W.; Gustafson, D. L.; Su, L. J.; Zirrolli, J. A.; Crighton, F.; Harrison, G. S.; Pierson, A. S.; Agarwal, R.; Glode, L. M. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest. New Drugs, 2007, 25(2), 139-46.
39. Siegel, A. B.; Narayan, R.; Rodriguez, R.; Goyal, A.; Jacobson, J. S.; Kelly, K.; Ladas, E.; Lunghofer, P. J.; Hansen, R. J.; Gustafson, D. L.; Flaig, T. W.; Tsai, W. Y.; Wu, D. P.; Lee, V.; Greenlee, H. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr. Cancer. Ther., 2014, 13(1), 46-53.
40. Sadava, D.; Kane, S. E. Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett., 2013, 339(1), 102-6.
41. Chang, H. R.; Chen, P. N.; Yang, S. F.; Sun, Y. S.; Wu, S. W.; Hung, T. W.; Lian, J. D.; Chu, S. C.; Hsieh, Y. S. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel. Mol. Carcinog., 2011, 50(10), 811-23.
42. Rho, J. K.; Choi, Y. J.; Jeon, B. S.; Choi, S. J.; Cheon, G. J.; Woo, S. K.; Kim, H. R.; Kim, C. H.; Choi, C. M.; Lee, J. C. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol. Cancer Ther., 2010, 9(12), 3233-43.
43. Noori-Daloii, M. R.; Saffari, M.; Raoofian, R.; Yekaninejad, M.; Dinehkabodi, O. S.; Noori-Daloii, A. R. The multidrug resistance pumps are inhibited by silibinin and apoptosis induced in K562 and KCL22 leukemia cell lines. Leuk. Res., 2014, 38(5), 575-80.
44. Dhanalakshmi, S.; Agarwal, P.; Glode, L. M.; Agarwal, R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- And carboplatin-induced growth inhibition and apoptotic death. Int. J. Cancer, 2003, 106(5), 699-705.
45. Tyagi, A. K.; Agarwal, C.; Chan, D. C.; Agarwal, R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol. Rep., 2004, 11(2), 493-9.
46. Flaig, T. W.; Su, L. J.; Harrison, G.; Agarwal, R.; Glode, L. M. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J. Cancer, 2007, 120(9), 2028-33.
47. Cufi, S.; Bonavia, R.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Corominas-Faja, B.; Cuyas, E.; Martin-Castillo, B.; Barrajon- Catalan, E.; Visa, J.; Segura-Carretero, A.; Joven, J.; Bosch- Barrera, J.; Micol, V.; Menendez, J. A. Silibinin suppresses EMTdriven erlotinib resistance by reversing the high miR-21/low miR- 200c signature in vivo. Sci. Rep., 2013, 3, 2459.
48. Hussain, S. A.; Marouf, B. H. Silibinin improves the cytotoxicity of methotrexate in chemo resistant human rhabdomyosarcoma cell lines. Saudi. Med. J., 2013, 34(11), 1145-50.
49. Nasiri, M.; Zarghami, N.; Koshki, K. N.; Mollazadeh, M.; Moghaddam, M. P.; Yamchi, M. R.; Esfahlan, R. J.; Barkhordari, A.; Alibakhshi, A. Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian. Pac. J. Cancer Prev., 2013, 14(6), 3449-53.
50. Ebrahimnezhad, Z.; Zarghami, N.; Keyhani, M.; Amirsaadat, S.; Akbarzadeh, A.; Rahmati, M.; Mohammad Taheri, Z.; Nejati- Koshki, K. Inhibition of hTERT Gene Expression by Silibinin- Loaded PLGA-PEG-Fe3O4 in T47D Breast Cancer Cell Line. Bioimpacts, 2013, 3(2), 67-74.
51. Thelen, P.; Wuttke, W.; Jarry, H.; Grzmil, M.; Ringert, R. H. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J. Urol., 2004, 171(5), 1934-8.
52. Zhang, S.; Yang, Y.; Liang, Z.; Duan, W.; Yang, J.; Yan, J.; Wang, N.; Feng, W.; Ding, M.; Nie, Y.; Jin, Z. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells. PLoS One, 2013, 8(12), e83699.
53. Kim, T. H.; Woo, J. S.; Kim, Y. K.; Kim, K. H. Silibinin induces cell death through reactive oxygen species-dependent downregulation of notch-1/ERK/Akt signaling in human breast cancer cells. J. Pharmacol. Exp. Ther., 2014, 349(2), 268-78.
54. Yousefi, M.; Ghaffari, S. H.; Zekri, A.; Hassani, S.; Alimoghaddam, K.; Ghavamzadeh, A. Silibinin induces apoptosis and inhibits proliferation of estrogen receptor (ER)-negative breast carcinoma cells through suppression of nuclear factor kappa B activation. Arch. Iran. Med., 2014, 17(5), 366-71.
55. Velmurugan, B.; Gangar, S. C.; Kaur, M.; Tyagi, A.; Deep, G.; Agarwal, R. Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm. Res., 2010, 27(10), 2085-97.
56. Chan, D. A.; Sutphin, P. D.; Nguyen, P.; Turcotte, S.; Lai, E. W.; Banh, A.; Reynolds, G. E.; Chi, J. T.; Wu, J.; Solow-Cordero, D. E.; Bonnet, M.; Flanagan, J. U.; Bouley, D. M.; Graves, E. E.; Denny, W. A.; Hay, M. P.; Giaccia, A. J. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med., 2011, 3(94), 94ra70.
57. Boheler, K. R.; Bhattacharya, S.; Kropp, E. M.; Chuppa, S.; Riordon, D. R.; Bausch-Fluck, D.; Burridge, P. W.; Wu, J. C.; Wersto, R. P.; Chan, G. C.; Rao, S.; Wollscheid, B.; Gundry, R. L. A human pluripotent stem cell surface N-glycoproteome resource reveals markers, extracellular epitopes, and drug targets. Stem Cell Reports, 2014, 3(1), 185-203.
58. Adams, D. J.; Ito, D.; Rees, M. G.; Seashore-Ludlow, B.; Puyang, X.; Ramos, A. H.; Cheah, J. H.; Clemons, P. A.; Warmuth, M.; Zhu, P.; Shamji, A. F.; Schreiber, S. L. NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes. ACS Chem. Biol., 2014.
59. Liu, Y.; Cao, Y.; Zhang, W.; Bergmeier, S.; Qian, Y.; Akbar, H.; Colvin, R.; Ding, J.; Tong, L.; Wu, S.; Hines, J.; Chen, X. A smallmolecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol. Cancer Ther., 2012, 11(8), 1672-82.
60. Murata, H.; Hruz, P. W.; Mueckler, M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem., 2000, 275(27), 20251-4.
61. Vyas, A. K.; Koster, J. C.; Tzekov, A.; Hruz, P. W. Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J. Biol. Chem., 2010, 285(47), 36395-400.
62. McBrayer, S. K.; Cheng, J. C.; Singhal, S.; Krett, N. L.; Rosen, S. T.; Shanmugam, M. Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter- directed therapy. Blood, 2012, 119(20), 4686-97.
63. Le Calve, B.; Rynkowski, M.; Le Mercier, M.; Bruyere, C.; Lonez, C.; Gras, T.; Haibe-Kains, B.; Bontempi, G.; Decaestecker, C.; Ruysschaert, J. M.; Kiss, R.; Lefranc, F. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia, 2010, 12(9), 727-39.
64. Krasnov, G. S.; Dmitriev, A. A.; Lakunina, V. A.; Kirpiy, A. A.; Kudryavtseva, A. V. Targeting VDAC-bound hexokinase II: A promising approach for concomitant anti-cancer therapy. Expert Opin. Ther. Targets, 2013, 17(10), 1221-33.
65. Mathupala, S. P.; Ko, Y. H.; Pedersen, P. L. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin. Cancer Biol., 2009, 19(1), 17-24.
66. Vander Heiden, M. G. Targeting cancer metabolism: A therapeutic window opens. Nat. Rev. Drug Discov., 2011, 10(9), 671-84.
67. El Mjiyad, N.; Caro-Maldonado, A.; Ramirez-Peinado, S.; Munoz- Pinedo, C. Sugar-free approaches to cancer cell killing. Oncogene, 2011, 30(3), 253-64.
68. Kuntz, S.; Mazerbourg, S.; Boisbrun, M.; Cerella, C.; Diederich, M.; Grillier-Vuissoz, I.; Flament, S. Energy restriction mimetic agents to target cancer cells: Comparison between 2-deoxyglucose and thiazolidinediones. Biochem. Pharmacol., 2014.
69. Butler, E. B.; Zhao, Y.; Munoz-Pinedo, C.; Lu, J.; Tan, M. Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance. Cancer Res., 2013, 73(9), 2709-17.
70. Landau, B. R.; Laszlo, J.; Stengle, J.; Burk, D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2- deoxy-D-glucose. J. Natl. Cancer Inst., 1958, 21(3), 485-94.
71. Dwarakanath, B. S.; Singh, D.; Banerji, A. K.; Sarin, R.; Venkataramana, N. K.; Jalali, R.; Vishwanath, P. N.; Mohanti, B. K.; Tripathi, R. P.; Kalia, V. K.; Jain, V. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res. Ther., 2009, 5 Suppl 1, S21-6.
72. Galluzzi, L.; Kepp, O.; Vander Heiden, M. G.; Kroemer, G. Metabolic targets for cancer therapy. Nat. Rev. Drug Discov., 2013, 12(11), 829-46.
73. Raez, L. E.; Papadopoulos, K.; Ricart, A. D.; Chiorean, E. G.; Dipaola, R. S.; Stein, M. N.; Rocha Lima, C. M.; Schlesselman, J. J.; Tolba, K.; Langmuir, V. K.; Kroll, S.; Jung, D. T.; Kurtoglu, M.; Rosenblatt, J.; Lampidis, T. J. A phase I dose-escalation trial of 2- deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2013, 71(2), 523-30.
74. Stein, M.; Lin, H.; Jeyamohan, C.; Dvorzhinski, D.; Gounder, M.; Bray, K.; Eddy, S.; Goodin, S.; White, E.; Dipaola, R. S. Targeting tumor metabolism with 2-deoxyglucose in patients with castrateresistant prostate cancer and advanced malignancies. Prostate, 2010, 70(13), 1388-94.
75. Corsi, G.; Palazzo, G. 1-Halobenzyl-1H-indazole-3-carboxylic acids. A new class of antispermatogenic agents. J. Med. Chem., 1976, 19(6), 778-83.
76. Floridi, A.; Paggi, M. G.; D'Atri, S.; De Martino, C.; Marcante, M. L.; Silvestrini, B.; Caputo, A. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res., 1981, 41(11 Pt 1), 4661-6.
77. Di, C. S.; Ferretti, G.; Papaldo, P.; Carlini, P.; Fabi, A.; Cognetti, F. Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today(Barc.), 2003, 39(3), 157-174.
78. Calvino, E.; Estan, M. C.; Simon, G. P.; Sancho, P.; Boyano- Adanez Mdel, C.; de Blas, E.; Breard, J.; Aller, P. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation. Biochem. Pharmacol., 2011, 82(11), 1619-29.
79. Lena, A.; Rechichi, M.; Salvetti, A.; Bartoli, B.; Vecchio, D.; Scarcelli, V.; Amoroso, R.; Benvenuti, L.; Gagliardi, R.; Gremigni, V.; Rossi, L. Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. J. Transl. Med., 2009, 7, 13.
80. Ricotti, L.; Tesei, A.; De Paola, F.; Milandri, C.; Amadori, D.; Frassineti, G. L.; Ulivi, P.; Zoli, W. Potentiation of antiproliferative drug activity by lonidamine in hepatocellular carcinoma cells. J. Chemother., 2003, 15(5), 480-7.
81. Teicher, B. A.; Herman, T. S.; Holden, S. A.; Epelbaum, R.; Liu, S. D.; Frei, E. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Res., 1991, 51(3), 780-4.
82. Teicher, B. A.; Holden, S. A.; Herman, T. S.; Frei, E. Modulation of alkylating agents by lonidamine in vivo. Semin. Oncol., 1991, 18(2 Suppl 4), 7-10.
83. Tanaka, J.; Teicher, B. A.; Herman, T. S.; Holden, S. A.; Dezube, B.; Frei, E. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo. Int. J. Cancer, 1991, 48(4), 631-7.
84. Fanciulli, M.; Bruno, T.; Giovannelli, A.; Gentile, F. P.; Di Padova, M.; Rubiu, O.; Floridi, A. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. Clin. Cancer Res., 2000, 6(4), 1590-7.
85. Li, Y. C.; Fung, K. P.; Kwok, T. T.; Lee, C. Y.; Suen, Y. K.; Kong, S. K. Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci., 2002, 71(23), 2729- 40.
86. Papaldo, P.; Lopez, M.; Cortesi, E.; Cammilluzzi, E.; Antimi, M.; Terzoli, E.; Lepidini, G.; Vici, P.; Barone, C.; Ferretti, G.; Di Cosimo, S.; Nistico, C.; Carlini, P.; Conti, F.; Di Lauro, L.; Botti, C.; Vitucci, C.; Fabi, A.; Giannarelli, D.; Marolla, P. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J. Clin. Oncol., 2003, 21(18), 3462-8.
87. Berruti, A.; Bitossi, R.; Gorzegno, G.; Bottini, A.; Alquati, P.; De Matteis, A.; Nuzzo, F.; Giardina, G.; Danese, S.; De Lena, M.; Lorusso, V.; Farris, A.; Sarobba, M. G.; DeFabiani, E.; Bonazzi, G.; Castiglione, F.; Bumma, C.; Moro, G.; Bruzzi, P.; Dogliotti, L.;Epirubicin-Lonidamine Group, O. T. I. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J. Clin. Oncol., 2002, 20(20), 4150-9.
88. Oudard, S.; Carpentier, A.; Banu, E.; Fauchon, F.; Celerier, D.; Poupon, M. F.; Dutrillaux, B.; Andrieu, J. M.; Delattre, J. Y. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J. Neurooncol., 2003, 63(1), 81-6.
89. De Lena, M.; Lorusso, V.; Latorre, A.; Fanizza, G.; Gargano, G.; Caporusso, L.; Guida, M.; Catino, A.; Crucitta, E.; Sambiasi, D.; Mazzei, A. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur. J. Cancer, 2001, 37(3), 364-8.
90. Porporato, P. E.; Dhup, S.; Dadhich, R. K.; Copetti, T.; Sonveaux, P. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front. Pharmacol., 2011, 2, 49.
91. Del Bufalo, D.; Trisciuoglio, D.; Scarsella, M.; D'Amati, G.; Candiloro, A.; Iervolino, A.; Leonetti, C.; Zupi, G. Lonidamine causes inhibition of angiogenesis-related endothelial cell functions. Neoplasia, 2004, 6(5), 513-22.
92. Milane, L.; Duan, Z.; Amiji, M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One, 2011, 6(9), e24075.
93. Milane, L.; Duan, Z. F.; Amiji, M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine, 2011, 7(4), 435-44.
94. Milane, L.;Duan, Z.; Amiji, M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm., 2011, 8(1), 185-203.
95. Nakano, A.; Tsuji, D.; Miki, H.; Cui, Q.; El Sayed, S. M.; Ikegame, A.; Oda, A.; Amou, H.; Nakamura, S.; Harada, T.; Fujii, S.; Kagawa, K.; Takeuchi, K.; Sakai, A.; Ozaki, S.; Okano, K.; Nakamura, T.; Itoh, K.; Matsumoto, T.; Abe, M. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One, 2011, 6(11), e27222.
96. Xu, R. H.; Pelicano, H.; Zhou, Y.; Carew, J. S.; Feng, L.; Bhalla, K. N.; Keating, M. J.; Huang, P. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 2005, 65(2), 613-21.
97. Cao, X.; Bloomston, M.; Zhang, T.; Frankel, W. L.; Jia, G.; Wang, B.; Hall, N. C.; Koch, R. M.; Cheng, H.; Knopp, M. V.; Sun, D. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin. Cancer Res., 2008, 14(6), 1831-9.
98. Ko, Y. H.; Smith, B. L.; Wang, Y.; Pomper, M. G.; Rini, D. A.; Torbenson, M. S.; Hullihen, J.; Pedersen, P. L. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun., 2004, 324(1), 269-75.
99. Zhou, Y.; Tozzi, F.; Chen, J.; Fan, F.; Xia, L.; Wang, J.; Gao, G.; Zhang, A.; Xia, X.; Brasher, H.; Widger, W.; Ellis, L. M.; Weihua, Z. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res., 2012, 72(1), 304-14.
100. Ko, Y. H.; Pedersen, P. L.; Geschwind, J. F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett., 2001, 173(1), 83-91.
101. Shoshan, M. C. 3-Bromopyruvate: Targets and outcomes. J. Bioenerg. Biomembr., 2012, 44(1), 7-15.
102. Ganapathy-Kanniappan, S.; Kunjithapatham, R.; Geschwind, J. F. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res., 2013, 33(1), 13-20.
103. Baltazar, F.; Pinheiro, C.; Morais-Santos, F.; Azevedo-Silva, J.; Queiros, O.; Preto, A.; Casal, M. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol. Histopathol., 2014.
104. Birsoy, K.; Wang, T.; Possemato, R.; Yilmaz, O. H.; Koch, C. E.; Chen, W. W.; Hutchins, A. W.; Gultekin, Y.; Peterson, T. R.; Carette, J. E.; Brummelkamp, T. R.; Clish, C. B.; Sabatini, D. M. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet., 2013, 45(1), 104- 8.
105. Ko, Y. H.; Verhoeven, H. A.; Lee, M. J.; Corbin, D. J.; Vogl, T. J.; Pedersen, P. L. A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J. Bioenerg. Biomembr., 2012, 44(1), 163-70.
106. Hulleman, E.;Kazemier, K. M.; Holleman, A.; VanderWeele, D. J.; Rudin, C. M.; Broekhuis, M. J.; Evans, W. E.; Pieters, R.; Den Boer, M. L. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 2009, 113(9), 2014-21.
107. Ros, S.; Schulze, A. Balancing glycolytic flux: The role of 6- phosphofructo-2-kinase/fructose 2, 6-bisphosphatases in cancer metabolism. Cancer Metab., 2013, 1(1), 8.
108. Atsumi, T.; Chesney, J.; Metz, C.; Leng, L.; Donnelly, S.; Makita, Z.; Mitchell, R.; Bucala, R. High expression of inducible 6- phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res., 2002, 62(20), 5881-7.
109. Kessler, R.; Bleichert, F.; Warnke, J. P.; Eschrich, K. 6- Phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas. J. Neurooncol., 2008, 86(3), 257-64.
110. Bobarykina, A. Y.; Minchenko, D. O.; Opentanova, I. L.; Moenner, M.; Caro, J.; Esumi, H.; Minchenko, O. H. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim. Pol., 2006, 53(4), 789-99.
111. Calvo, M. N.; Bartrons, R.; Castano, E.; Perales, J. C.; Navarro- Sabate, A.; Manzano, A. PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS Lett., 2006, 580(13), 3308-14.
112. Yalcin, A.; Clem, B. F.; Imbert-Fernandez, Y.; Ozcan, S. C.; Peker, S.; O'Neal, J.; Klarer, A. C.; Clem, A. L.; Telang, S.; Chesney, J. 6- Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell. Death. Dis., 2014, 5, e1337.
113. De Bock, K.; Georgiadou, M.; Schoors, S.; Kuchnio, A.; Wong, B. W.; Cantelmo, A. R.; Quaegebeur, A.; Ghesquiere, B.; Cauwenberghs, S.; Eelen, G.; Phng, L. K.; Betz, I.; Tembuyser, B.; Brepoels, K.; Welti, J.; Geudens, I.; Segura, I.; Cruys, B.; Bifari, F.; Decimo, I.; Blanco, R.; Wyns, S.; Vangindertael, J.; Rocha, S.; Collins, R. T.; Munck, S.; Daelemans, D.; Imamura, H.; Devlieger, R.; Rider, M.; Van Veldhoven, P. P.; Schuit, F.; Bartrons, R.; Hofkens, J.; Fraisl, P.; Telang, S.; Deberardinis, R. J.; Schoonjans, L.; Vinckier, S.; Chesney, J.; Gerhardt, H.; Dewerchin, M.; Carmeliet, P. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell, 2013, 154(3), 651-63.
114. Clem, B.; Telang, S.; Clem, A.; Yalcin, A.; Meier, J.; Simmons, A.; Rasku, M. A.; Arumugam, S.; Dean, W. L.; Eaton, J.; Lane, A.; Trent, J. O.; Chesney, J. Small-molecule inhibition of 6- phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther., 2008, 7(1), 110-20.
115. Klarer, A. C.; O'Neal, J.; Imbert-Fernandez, Y.; Clem, A.; Ellis, S. R.; Clark, J.; Clem, B.; Chesney, J.; Telang, S. Inhibition of 6- phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab., 2014, 2(1), 2.
116. Clem, B. F.; O'Neal, J.; Tapolsky, G.; Clem, A. L.; Imbert- Fernandez, Y.; Kerr, D. A. 2nd; Klarer, A. C.; Redman, R.; Miller, D. M.; Trent, J. O.; Telang, S.; Chesney, J. Targeting 6- phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol. Cancer Ther., 2013, 12(8), 1461-70.
117. Schoors, S.; De Bock, K.; Cantelmo, A. R.; Georgiadou, M.; Ghesquiere, B.; Cauwenberghs, S.; Kuchnio, A.; Wong, B. W.; Quaegebeur, A.; Goveia, J.; Bifari, F.; Wang, X.; Blanco, R.; Tembuyser, B.; Cornelissen, I.; Bouche, A.; Vinckier, S.; Diaz-Moralli, S.; Gerhardt, H.; Telang, S.; Cascante, M.; Chesney, J.; Dewerchin, M.; Carmeliet, P. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab., 2014, 19(1), 37-48.
118. Christofk, H. R.; Vander Heiden, M. G.; Harris, M. H.; Ramanathan, A.; Gerszten, R. E.; Wei, R.; Fleming, M. D.; Schreiber, S. L.; Cantley, L. C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 2008, 452(7184), 230-3.
119. Iqbal, M. A.; Gupta, V.; Gopinath, P.; Mazurek, S.; Bamezai, R. N. Pyruvate kinase M2 and cancer: An updated assessment. FEBS Lett., 2014, 588(16), 2685-92.
120. Dombrauckas, J. D.; Santarsiero, B. D.; Mesecar, A. D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry, 2005, 44(27), 9417-29.
121. Li, Z.; Yang, P.; Li, Z. The multifaceted regulation and functions of PKM2 in tumor progression. Biochim. Biophys. Acta, 2014, 1846(2), 285-296.
122. Anastasiou, D.; Yu, Y.; Israelsen, W. J.; Jiang, J. K.; Boxer, M. B.; Hong, B. S.; Tempel, W.; Dimov, S.; Shen, M.; Jha, A.; Yang, H.; Mattaini, K. R.; Metallo, C. M.; Fiske, B. P.; Courtney, K. D.; Malstrom, S.; Khan, T. M.; Kung, C.; Skoumbourdis, A. P.; Veith, H.; Southall, N.; Walsh, M. J.; Brimacombe, K. R.; Leister, W.; Lunt, S. Y.; Johnson, Z. R.; Yen, K. E.; Kunii, K.; Davidson, S. M.; Christofk, H. R.; Austin, C. P.; Inglese, J.; Harris, M. H.; Asara, J. M.; Stephanopoulos, G.; Salituro, F. G.; Jin, S.; Dang, L.; Auld, D. S.; Park, H. W.; Cantley, L. C.; Thomas, C. J.; Vander Heiden, M. G. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol., 2012, 8(10), 839-47.
123. Kung, C.; Hixon, J.; Choe, S.; Marks, K.; Gross, S.; Murphy, E.; DeLaBarre, B.; Cianchetta, G.; Sethumadhavan, S.; Wang, X.; Yan, S.; Gao, Y.; Fang, C.; Wei, W.; Jiang, F.; Wang, S.; Qian, K.; Saunders, J.; Driggers, E.; Woo, H. K.; Kunii, K.; Murray, S.; Yang, H.; Yen, K.; Liu, W.; Cantley, L. C.; Vander Heiden, M. G.; Su, S. M.; Jin, S.; Salituro, F. G.; Dang, L. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol., 2012, 19(9), 1187-98.
124. Yang, W.; Xia, Y.; Ji, H.; Zheng, Y.; Liang, J.; Huang, W.; Gao, X.; Aldape, K.; Lu, Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature, 2011, 480(7375), 118- 22.
125. Granchi, C.; Paterni, I.; Rani, R.; Minutolo, F. Small-molecule inhibitors of human LDH5. Future Med. Chem., 2013, 5(16), 1967- 91.
126. Doherty, J. R.; Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest., 2013, 123(9), 3685-92.
127. Firth, J. D.; Ebert, B. L.; Ratcliffe, P. J. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J. Biol. Chem., 1995, 270(36), 21021-7.
128. Miao, P.; Sheng, S.; Sun, X.; Liu, J.; Huang, G. Lactate dehydrogenase A in cancer: A promising target for diagnosis and therapy. IUBMB Life, 2013, 65(11), 904-10.
129. Teke, H. U.; Basak, M.; Teke, D.; Kanbay, M. Serum Level of Lactate Dehydrogenase is a Useful Clinical Marker to Monitor Progressive Multiple Myeloma Diseases: A Case Report. Turk. J. Haematol., 2014, 31(1), 84-7.
130. Yu, Y.; Deck, J. A.; Hunsaker, L. A.; Deck, L. M.; Royer, R. E.; Goldberg, E.; Vander Jagt, D. L. Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem. Pharmacol., 2001, 62(1), 81-9.
131. Baggstrom, M. Q.; Qi, Y.; Koczywas, M.; Argiris, A.; Johnson, E. A.; Millward, M. J.; Murphy, S. C.; Erlichman, C.; Rudin, C. M.; Govindan, R. A phase II study of AT-101 (Gossypol) in chemotherapy- sensitive recurrent extensive-stage small cell lung cancer. J. Thorac. Oncol., 2011, 6(10), 1757-60.
132. Heist, R. S.; Fain, J.; Chinnasami, B.; Khan, W.; Molina, J. R.; Sequist, L. V.; Temel, J. S.; Fidias, P.; Brainerd, V.; Leopold, L.; Lynch, T. J. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J. Thorac. Oncol., 2010, 5(10), 1637-43.
133. Le, A.; Cooper, C. R.; Gouw, A. M.; Dinavahi, R.; Maitra, A.; Deck, L. M.; Royer, R. E.; Vander Jagt, D. L.; Semenza, G. L.; Dang, C. V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(5), 2037-42.
134. Granchi, C.; Roy, S.; Giacomelli, C.; Macchia, M.; Tuccinardi, T.; Martinelli, A.; Lanza, M.; Betti, L.; Giannaccini, G.; Lucacchini, A.; Funel, N.; Leon, L. G.; Giovannetti, E.; Peters, G. J.; Palchaudhuri, R.; Calvaresi, E. C.; Hergenrother, P. J.; Minutolo, F. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J. Med. Chem., 2011, 54(6), 1599-612.
135. Pinheiro, C.; Longatto-Filho, A.; Azevedo-Silva, J.; Casal, M.; Schmitt, F. C.; Baltazar, F. Role of monocarboxylate transporters in human cancers: state of the art. J. Bioenerg. Biomembr., 2012, 44(1), 127-39.
136. Adijanto, J.; Philp, N. J. The SLC16A family of monocarboxylate transporters (MCTs)-physiology and function in cellular metabolism, pH homeostasis, and fluid transport. Curr. Top. Membr., 2012, 70, 275-311.
137. Sonveaux, P.; Vegran, F.; Schroeder, T.; Wergin, M. C.; Verrax, J.; Rabbani, Z. N.; De Saedeleer, C. J.; Kennedy, K. M.; Diepart, C.; Jordan, B. F.; Kelley, M. J.; Gallez, B.; Wahl, M. L.; Feron, O.; Dewhirst, M. W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest., 2008, 118(12), 3930-42.
138. Ovens, M. J.; Davies, A. J.; Wilson, M. C., et al. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem. J., 2010, 425(3), 523-30.
139. Enerson, B. E.; Drewes, L. R. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J. Pharm. Sci., 2003, 92(8), 1531-44.
140. Miranda-Goncalves, V.; Honavar, M.; Pinheiro, C.; Martinho, O.; Pires, M. M.; Pinheiro, C.; Cordeiro, M.; Bebiano, G.; Costa, P.; Palmeirim, I.; Reis, R. M.; Baltazar, F. Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets. Neuro. Oncol., 2013, 15(2), 172-88.
141. Morais-Santos, F.; Miranda-Goncalves, V.; Pinheiro, S.; Vieira, A. F.; Paredes, J.; Schmitt, F. C.; Baltazar, F.; Pinheiro, C. Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. Endocr. Relat. Cancer, 2014, 21(1), 27-38.
142. Le Floch, R.; Chiche, J.; Marchiq, I.; Naiken, T.; Ilc, K.; Murray, C. M.; Critchlow, S. E.; Roux, D.; Simon, M. P.; Pouyssegur, J. CD147 subunit of lactate/H+ symporters MCT1 and hypoxiainducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. U. S. A., 2011, 108(40), 16663-8.
143. Afonso, J.; Santos, L. L.; Miranda-Goncalves, V.; Morais, A.; Amaro, T.; Longatto-Filho, A.; Baltazar, F. CD147 and MCT1- potential partners in bladder cancer aggressiveness and cisplatin resistance. Mol. Carcinog., 2014.
144. de Oliveira, A. T.; Pinheiro, C.; Longatto-Filho, A.; Brito, M. J.; Martinho, O.; Matos, D.; Carvalho, A. L.; Vazquez, V. L.; Silva, T. B.; Scapulatempo, C.; Saad, S. S.; Reis, R. M.; Baltazar, F. Coexpression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J. Bioenerg. Biomembr., 2012, 44(1), 171-8.
145. Pertega-Gomes, N.; Vizcaino, J. R.; Miranda-Goncalves, V.; Pinheiro, C.; Silva, J.; Pereira, H.; Monteiro, P.; Henrique, R. M.; Reis, R. M.; Lopes, C.; Baltazar, F. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer, 2011, 11, 312.
146. Pinheiro, C.; Longatto-Filho, A.; Simoes, K.; Jacob, C. E.; Bresciani, C. J.; Zilberstein, B.; Cecconello, I.; Alves, V. A.; Schmitt, F.; Baltazar, F. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur. J. Cancer, 2009, 45(13), 2418-24.
147. Pinheiro, C.; Longatto-Filho, A.; Pereira, S. M.; Etlinger, D.; Moreira, M. A.; Jube, L. F.; Queiroz, G. S.; Schmitt, F.; Baltazar, F. Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Dis. Markers, 2009, 26(3), 97-103.
148. Chen, H.; Wang, L.; Beretov, J.; Hao, J.; Xiao, W.; Li, Y. Coexpression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin. Exp. Metastasis, 2010, 27(8), 557-69.
149. Pinheiro, C.; Albergaria, A.; Paredes, J.; Sousa, B.; Dufloth, R.; Vieira, D.; Schmitt, F.; Baltazar, F. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology, 2010, 56(7), 860-7.
150. Slomiany, M. G.; Grass, G. D.; Robertson, A. D.; Yang, X. Y.; Maria, B. L.; Beeson, C.; Toole, B. P. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res., 2009, 69(4), 1293-301.
151. Baba, M.; Inoue, M.; Itoh, K.; Nishizawa, Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem. Biophys. Res. Commun., 2008, 374(1), 111-6.
152. Schneiderhan, W.; Scheler, M.; Holzmann, K. H., et al. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut, 2009, 58(10), 1391-8.
153. Xiong, L.; Edwards, C. K. 3rd, and Zhou, L. The biological function and clinical utilization of CD147 in human diseases: A review of the current scientific literature. Int. J. Mol. Sci., 2014, 15(10), 17411-41.
154. Kasinrerk, W.; Tokrasinwit, N.; Phunpae, P. CD147 monoclonal antibodies induce homotypic cell aggregation of monocytic cell line U937 via LFA-1/ICAM-1 pathway. Immunology, 1999, 96(2), 184-92.
155. Patel, M. S.; Nemeria, N. S.; Furey, W.; Jordan, F. The pyruvate dehydrogenase complexes: structure-based function and regulation. J. Biol. Chem., 2014, 289(24), 16615-23.
156. Dunbar, E. M.; Coats, B. S.; Shroads, A. L.; Langaee, T.; Lew, A.; Forder, J. R.; Shuster, J. J.; Wagner, D. A.; Stacpoole, P. W. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest. New Drugs, 2014, 32(3), 452-64.
157. Whitehouse, S.; Randle, P. J. Activation of pyruvate dehydrogenase in perfused rat heart by dichloroacetate (Short Communication). Biochem. J., 1973, 134(2), 651-3.
158. Knoechel, T. R.; Tucker, A. D.; Robinson, C. M.; Phillips, C.; Taylor, W.; Bungay, P. J.; Kasten, S. A.; Roche, T. E.; Brown, D. G. Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. Biochemistry, 2006, 45(2), 402-15.
159. Michelakis, E. D.; Webster, L.; Mackey, J. R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer, 2008, 99(7), 989-94.
160. Bonnet, S.; Archer, S. L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C. T.; Lopaschuk, G. D.; Puttagunta, L.; Bonnet, S.; Harry, G.; Hashimoto, K.; Porter, C. J.; Andrade, M. A.; Thebaud, B.; Michelakis, E. D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell., 2007, 11(1), 37-51.
161. Stacpoole, P. W. The pharmacology of dichloroacetate. Metab., 1989, 38(11), 1124-44.
162. Michelakis, E. D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T. L.; Mackey, J. R.; Fulton, D.; Abdulkarim, B.; McMurtry, M. S.; Petruk, K. C. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med., 2010, 2(31), 31ra34.
163. Kankotia, S.; Stacpoole, P. W. Dichloroacetate and cancer: New home for an orphan drug? Biochim. Biophys. Acta, 2014.
164. Garon, E. B.; Christofk, H. R.; Hosmer, W.; Britten, C. D.; Bahng, A.; Crabtree, M. J.; Hong, C. S.; Kamranpour, N.; Pitts, S.; Kabbinavar, F.; Patel, C.; von Euw, E.; Black, A.; Michelakis, E. D.; Dubinett, S. M.; Slamon, D. J. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J. Cancer Res. Clin. Oncol., 2014, 140(3), 443-52.
165. Guaragnella, N.; Giannattasio, S.; Moro, L. Mitochondrial dysfunction in cancer chemoresistance. Biochem. Pharmacol., 2014.
166. Hundal, R. S.; Krssak, M.; Dufour, S.; Laurent, D.; Lebon, V.; Chandramouli, V.; Inzucchi, S. E.; Schumann, W. C.; Petersen, K. F.; Landau, B. R.; Shulman, G. I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49(12), 2063-9.
167. Dykens, J. A.; Jamieson, J.; Marroquin, L.; Nadanaciva, S.; Billis, P. A.; Will, Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol. Appl. Pharmacol., 2008, 233(2), 203-10.
168. Owen, M. R.; Doran, E.; Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J., 2000, 348 Pt 3, 607-14.
169. Shaw, R. J.; Kosmatka, M.; Bardeesy, N.; Hurley, R. L.; Witters, L. A.; DePinho, R. A.; Cantley, L. C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(10), 3329-35.
170. Zakikhani, M.; Dowling, R.; Fantus, I. G.; Sonenberg, N.; Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res., 2006, 66(21), 10269-73.
171. Ben Sahra, I.; Laurent, K.; Giuliano, S.; Larbret, F.; Ponzio, G.; Gounon, P.; Le Marchand-Brustel, Y.; Giorgetti-Peraldi, S.; Cormont, M.; Bertolotto, C.; Deckert, M.; Auberger, P.; Tanti, J. F.; Bost, F. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res., 2010, 70(6), 2465-75.
172. Cheong, J. H.; Park, E. S.; Liang, J.; Dennison, J. B.; Tsavachidou, D.; Nguyen-Charles, C.; Wa Cheng, K.; Hall, H.; Zhang, D.; Lu, Y.; Ravoori, M.; Kundra, V.; Ajani, J.; Lee, J. S.; Ki Hong, W.; Mills, G. B. Dual inhibition of tumor energy pathway by 2- deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther., 2011, 10(12), 2350-62.
173. Haugrud, A. B.; Zhuang, Y.; Coppock, J. D.; Miskimins, W. K. Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. Breast Cancer Res. Treat., 2014, 147(3), 539-50.
174. Evans, J. M.; Donnelly, L. A.; Emslie-Smith, A. M.; Alessi, D. R.; Morris, A. D. Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005, 330(7503), 1304-5.
175. Kasznicki, J.; Sliwinska, A.; Drzewoski, J. Metformin in cancer prevention and therapy. Ann. Transl. Med., 2014, 2(6), 57.
176. Cioce, M.; Valerio, M.; Casadei, L.; Pulito, C.; Sacconi, A.; Mori, F.; Biagioni, F.; Manetti, C.; Muti, P.; Strano, S.; Blandino, G. Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget., 2014, 5(12), 4129-43.
177. Algire, C.; Amrein, L.; Bazile, M.; David, S.; Zakikhani, M.; Pollak, M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene, 2011, 30(10), 1174-82.
178. Alimova, I. N.; Liu, B.; Fan, Z.; Edgerton, S. M.; Dillon, T.; Lind, S. E.; Thor, A. D. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle, 2009, 8(6), 909-15.
179. Gotlieb, W. H.; Saumet, J.; Beauchamp, M. C.; Gu, J.; Lau, S.; Pollak, M. N.; Bruchim, I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol., 2008, 110(2), 246-50.
180. Lengyel, E.; Litchfield, L. M.; Mitra, A. K.; Nieman, K. M.; Mukherjee, A.; Zhang, Y.; Johnson, A.; Bradaric, M.; Lee, W.; Romero, I. L. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am. J. Obstet. Gynecol., 2014.
181. Hanusova, V.; Skalova, L.; Kralova, V.; Matouskova, P. Potential Anti-cancer Drugs Commonly Used for Other Indications. Curr. Cancer. Drug Targets, 2015, 15(1), 35-52.
182. Del Barco, S.; Vazquez-Martin, A.; Cufi, S.; Oliveras-Ferraros, C.; Bosch-Barrera, J.; Joven, J.; Martin-Castillo, B.; Menendez, J. A. Metformin: multi-faceted protection against cancer. Oncotarget, 2011, 2(12), 896-917.
183. Muti, P.; Berrino, F.; Krogh, V.; Villarini, A.; Barba, M.; Strano, S.; Blandino, G. Metformin, diet and breast cancer: An avenue for chemoprevention. Cell Cycle, 2009, 8(16), 2661.
184. Martin-Castillo, B.; Dorca, J.; Vazquez-Martin, A.; Oliveras- Ferraros, C.; Lopez-Bonet, E.; Garcia, M.; Del Barco, S.; Menendez, J. A. Incorporating the antidiabetic drug metformin in HER2- positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: An ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann. Oncol., 2010, 21(1), 187- 9.
185. Ganapathy-Kanniappan, S.; Geschwind, J. F. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol. Cancer, 2013, 12, 152.
186. Hasmim, M.; Messai, Y.; Noman, M. Z.; Chouaib, S. [Tumor hypoxia: A key player in the regulation of stromal and anti-tumor responses]. Med. Sci. (Paris), 2014, 30(4), 422-8.
187. De Milito, A.; Fais, S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol., 2005, 1(6), 779-86.
188. Backos, D. S.; Franklin, C. C.; Reigan, P. The role of glutathione in brain tumor drug resistance. Biochem. Pharmacol., 2012, 83(8), 1005-12.
189. Maschek, G.; Savaraj, N.; Priebe, W.; Braunschweiger, P.; Hamilton, K.; Tidmarsh, G. F.; De Young, L. R.; Lampidis, T. J. 2- deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res., 2004, 64(1), 31-4.
190. Sullivan, E. J.; Kurtoglu, M.; Brenneman, R.; Liu, H.; Lampidis, T. J. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother. Pharmacol., 2014, 73(2), 417-27.
191. Del Bufalo, D.; Biroccio, A.; Soddu, S.; Laudonio, N.; D'Angelo, C.; Sacchi, A.; Zupi, G. Lonidamine induces apoptosis in drugresistant cells independently of the p53 gene. J. Clin. Invest., 1996, 98(5), 1165-73.
192. Tennant, D. A.; Duran, R. V.; Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer, 2010, 10(4), 267-77.
193. Ianniello, G. P.; De Cataldis, G.; Comella, P.; Scarpati, M. D.; Maiorino, A.; Brancaccio, L.; Cioffi, R.; Lombardi, A.; Carnicelli, P.; Tinessa, V. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial. Cancer, 1996, 78(1), 63-9.
194. Orlandi, L.; Zaffaroni, N.; Gornati, D.; Veneroni, S.; Silvestrini, R. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer. Anticancer Res., 1994, 14(3a), 1161-4.
195. Dogliotti, L.; Berruti, A.; Buniva, T.; Zola, P.; Bau, M. G.; Farris, A.; Sarobba, M. G.; Bottini, A.; Alquati, P.; Deltetto, F.; Gosso, P.; Monzeglio, C.; Moro, G.; Sussio, M.; Perroni, D. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial. J. Clin. Oncol., 1996, 14(4), 1165-72.
196. Bean, J. F.; Qiu, Y. Y.; Yu, S.; Clark, S.; Chu, F.; Madonna, M. B. Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma. J. Pediatr. Surg., 2014, 49(6), 981-4; discussion 984.
197. Zhai, X.; Yang, Y.; Wan, J.; Zhu, R.; Wu, Y. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol. Rep., 2013, 30(6), 2983-91.
198. Hua, G.; Liu, Y.; Li, X.; Xu, P.; Luo, Y. Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A. Oncol. Rep., 2014, 31(6), 2727-34.
199. Li, X.; Zhao, H.; Zhou, X.; Song, L. Inhibition of lactate dehydrogenase A by microRNA34a resensitizes colon cancer cells to 5fluorouracil. Mol. Med. Rep., 2015, 11(1), 577-82.
200. Zheng, M. F.; Shen, S. Y.; Huang, W. D. DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft. Cancer Chemother. Pharmacol., 2013, 72(5), 1031-41.
201. Fiebiger, W.; Olszewski, U.; Ulsperger, E.; Geissler, K.; Hamilton, G. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin. Transl. Oncol., 2011, 13(1), 43-9.
202. Xuan, Y.; Hur, H.; Ham, I. H.; Yun, J.; Lee, J. Y.; Shim, W.; Kim, Y. B.; Lee, G.; Han, S. U.; Cho, Y. K. Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism. Exp. Cell Res., 2014, 321(2), 219-30.
203. Kumar, A.; Kant, S.; Singh, S. M. Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: A role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation. Toxicol. Appl. Pharmacol., 2013, 273(1), 196-208.
204. Zong, W. X.; Ditsworth, D.; Bauer, D. E.; Wang, Z. Q.; Thompson, C. B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev., 2004, 18(11), 1272-82.
205. Lemmon, M. A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2010, 141(7), 1117-34.
206. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature, 2001, 411(6835), 355-365.
207. Amit, I.; Wides, R.; Yarden, Y. Evolvable signaling networks of receptor tyrosine kinases: Relevance of robustness to malignancy and to cancer therapy. Mol. Syst. Biol., 2007, 3, 151.
208. Drevs, J.; Medinger, M.; Schmidt-Gersbach, C.; Weber, R.; Unger, C. Receptor tyrosine kinases: The main targets for new anticancer therapy. Curr. Drug Targets, 2003, 4(2), 113-21.
209. Jurgensmeier, J. M.; Eder, J. P.; Herbst, R. S. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin. Cancer Res., 2014, 20(17), 4425-35.
210. Stegmeier, F.; Warmuth, M.; Sellers, W. R.; Dorsch, M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther., 2010, 87(5), 543-52.
211. Jonkers, J.; Berns, A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell, 2004, 6(6), 535-8.
212. Chong, C. R.; Janne, P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med., 2013, 19(11), 1389- 400.
213. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer, 2005, 5(5), 341-54.
214. Xu, A. M.; Huang, P. H. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res., 2010, 70(10), 3857-60.
215. Shawver, L. K.; Slamon, D.; Ullrich, A. Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell, 2002, 1(2), 117- 23.
216. Demetri, G. D.; von Mehren, M.; Blanke, C. D.; Van den Abbeele, A. D.; Eisenberg, B.; Roberts, P. J.; Heinrich, M. C.; Tuveson, D. A.; Singer, S.; Janicek, M.; Fletcher, J. A.; Silverman, S. G.; Silberman, S. L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B. J.; Corless, C.; Fletcher, C. D.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002, 347(7), 472-80.
217. Mason, E. F.; Zhao, Y.; Goraksha-Hicks, P.; Coloff, J. L.; Gannon, H.; Jones, S. N.; Rathmell, J. C. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res., 2010, 70(20), 8066-76.
218. Gottschalk, S.; Anderson, N.; Hainz, C.; Eckhardt, S. G.; Serkova, N. J.Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin. Cancer Res., 2004, 10(19), 6661-8.
219. Klawitter, J.; Kominsky, D. J.; Brown, J. L.; Klawitter, J.; Christians, U.; Leibfritz, D.; Melo, J. V.; Eckhardt, S. G.; Serkova, N. J. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br. J. Pharmacol., 2009, 158(2), 588-600.
220. Kluza, J.; Jendoubi, M.; Ballot, C.; Dammak, A.; Jonneaux, A.; Idziorek, T.; Joha, S.; Dauphin, V.; Malet-Martino, M.; Balayssac, S.; Maboudou, P.; Briand, G.; Formstecher, P.; Quesnel, B.; Marchetti, P. Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS One, 2011, 6(7), e21924.
221. Kominsky, D. J.; Klawitter, J.; Brown, J. L.; Boros, L. G.; Melo, J. V.; Eckhardt, S. G.; Serkova, N. J. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin. Cancer Res., 2009, 15(10), 3442-50.
222. Boros, L. G.; Cascante, M.; Lee, W. N. Metabolic profiling of cell growth and death in cancer: Applications in drug discovery. Drug Discov. Today, 2002, 7(6), 364-72.
223. Serkova, N.; Boros, L. G. Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. Am. J. Pharmacogenomics, 2005, 5(5), 293-302.
224. Barnes, K.; McIntosh, E.; Whetton, A. D.; Daley, G. Q.; Bentley, J.; Baldwin, S. A. Chronic myeloid leukaemia: An investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene, 2005, 24(20), 3257-67.
225. Boren, J.; Cascante, M.; Marin, S.; Comin-Anduix, B.; Centelles, J. J.; Lim, S.; Bassilian, S.; Ahmed, S.; Lee, W. N.; Boros, L. G. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J. Biol. Chem., 2001, 276(41), 37747-53.
226. Bentley, J.; Walker, I.; McIntosh, E.; Whetton, A. D.; Owen- Lynch, P. J.; Baldwin, S. A. Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model. Br. J. Haematol., 2001, 112(1), 212-5.
227. Bentley, J.; Itchayanan, D.; Barnes, K.; McIntosh, E.; Tang, X.; Downes, C. P.; Holman, G. D.; Whetton, A. D.; Owen-Lynch, P. J.; Baldwin, S. A. Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J. Biol. Chem., 2003, 278(41), 39337-48.
228. Zhao, F.; Mancuso, A.; Bui, T. V.; Tong, X.; Gruber, J. J.; Swider, C. R.; Sanchez, P. V.; Lum, J. J.; Sayed, N.; Melo, J. V.; Perl, A. E.; Carroll, M.; Tuttle, S. W.; Thompson, C. B. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF- 1alpha-induced metabolic reprograming. Oncogene, 2010, 29(20), 2962-72.
229. Giuntoli, S.; Tanturli, M.; Di Gesualdo, F.; Barbetti, V.; Rovida, E.; Dello Sbarba, P. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate. Haematologica, 2011, 96(2), 204-12.
230. Martinez Marignac, V. L.; Smith, S.; Toban, N.; Bazile, M.; Aloyz, R. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic reprogramming. Oncotarget, 2013, 4(12), 2550-66.
231. Fumarola, C.; Caffarra, C.; La Monica, S.; Galetti, M.; Alfieri, R. R.; Cavazzoni, A.; Galvani, E.; Generali, D.; Petronini, P. G.; Bonelli, M. A. Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling. Breast Cancer Res. Treat., 2013, 141(1), 67-78.
232. Hudson, C. D.; Hagemann, T.; Mather, S. J.; Avril, N. Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell Death Dis., 2014, 5, e1160.
233. Makinoshima, H.; Takita, M.; Matsumoto, S.; Yagishita, A.; Owada, S.; Esumi, H.; Tsuchihara, K. Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma. J. Biol. Chem., 2014, 289(30), 20813-20823.
234. Velpula, K. K.; Bhasin, A.; Asuthkar, S.; Tsung, A. J. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res., 2013, 73(24), 7277- 89.
235. Su, H.; Bodenstein, C.; Dumont, R. A.; Seimbille, Y.; Dubinett, S.; Phelps, M. E.; Herschman, H.; Czernin, J.; Weber, W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res., 2006, 12(19), 5659-67.
236. Li, X.; Lu, Y.; Liang, K.; Pan, T.; Mendelsohn, J.; Fan, Z. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol. Cancer Ther., 2008, 7(5), 1207-17.
237. Lu, Y.; Liang, K.; Li, X.; Fan, Z. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol. Cancer, 2007, 6, 63.
238. Lu, H.; Li, X.; Luo, Z.; Liu, J.; Fan, Z. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Mol. Cancer Ther., 2013, 12(10), 2187-99.
239. Monteleone, F.; Rosa, R.; Vitale, M.; D'Ambrosio, C.; Succoio, M.; Formisano, L.; Nappi, L.; Romano, M. F.; Scaloni, A.; Tortora, G.; Bianco, R.; Zambrano, N. Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics, 2013, 13(5), 866-77.
240. KKomurov, K.; Tseng, J. T.; Muller, M.; Seviour, E. G.; Moss, T. J.; Yang, L.; Nagrath, D.; Ram, P. T. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2- positive breast cancer cells. Mol. Syst. Biol., 2012, 8, 596.
241. Kim, S. M.; Yun, M. R.; Hong, Y. K.; Solca, F.; Kim, J. H.; Kim, H. J.; Cho, B. C. Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol. Cancer Ther., 2013, 12(10), 2145-56.
242. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 2011, 364(26), 2507-16.
243. Lee, M. H.; Lee, S. E.; Kim, D. W.; Ryu, M. J.; Kim, S. J.; Kim, S. J.; Kim, Y. K.; Park, J. H.; Kweon, G. R.; Kim, J. M.; Lee, J. U.; De Falco, V.; Jo, Y. S.; Shong, M. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: A clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J. Clin. Endocrinol. Metab., 2011, 96(1), E19-E30.
244. Parmenter, T. J.; Kleinschmidt, M.; Kinross, K. M.; Bond, S. T.; Li, J.; Kaadige, M. R.; Rao, A.; Sheppard, K. E.; Hugo, W.; Pupo, G. M.; Pearson, R. B.; McGee, S. L.; Long, G. V.; Scolyer, R. A.; Rizos, H.; Lo, R. S.; Cullinane, C.; Ayer, D. E.; Ribas, A.; Johnstone, R. W.; Hicks, R. J.; McArthur, G. A. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov., 2014, 4(4), 423-33.
245. Falck Miniotis, M.; Arunan, V.; Eykyn, T. R.; Marais, R.; Workman, P.; Leach, M. O.; Beloueche-Babari, M. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. Cancer Res., 2013, 73(13), 4039-49.
246. Kluza, J.; Corazao-Rozas, P.; Touil, Y.; Jendoubi, M.; Maire, C.; Guerreschi, P.; Jonneaux, A.; Ballot, C.; Balayssac, S.; Valable, S.; Corroyer-Dulmont, A.; Bernaudin, M.; Malet-Martino, M.; de Lassalle, E. M.; Maboudou, P.; Formstecher, P.; Polakowska, R.; Mortier, L.; Marchetti, P. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res., 2012, 72(19), 5035-47.
247. Strohecker, A. M.; White, E. Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov., 2014, 4(7), 766-72.
248. Ostergaard, L.; Tietze, A.; Nielsen, T.; Drasbek, K. R.; Mouridsen, K.; Jespersen, S. N.; Horsman, M. R.. The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res., 2013, 73(18), 5618-24.
249. Baker, G. J.; Yadav, V. N.; Motsch, S.; Koschmann, C.; Calinescu, A. A.; Mineharu, Y.; Camelo-Piragua, S. I.; Orringer, D.; Bannykh, S.; Nichols, W. S.; deCarvalho, A. C.; Mikkelsen, T.; Castro, M. G.; Lowenstein, P. R. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia, 2014, 16(7), 543-61.
250. Rapisarda, A.; Hollingshead, M.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Gehrs, B.; Raffeld, M.; Kinders, R. J.; Parchment, R.; Anver, M. R.; Shoemaker, R. H.; Melillo, G. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther., 2009, 8(7), 1867-77.
251. Kumar, K.; Wigfield, S.; Gee, H. E.; Devlin, C. M.; Singleton, D.; Li, J. L.; Buffa, F.; Huffman, M.; Sinn, A. L.; Silver, J.; Turley, H.; Leek, R.; Harris, A. L.; Ivan, M. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. J. Mol. Med. (Berl), 2013, 91(6), 749-58.
252. Fack, F.; Espedal, H.; Keunen, O.; Golebiewska, A.; Obad, N.; Harter, P. N.; Mittelbronn, M.; Bahr, O.; Weyerbrock, A.; Stuhr, L.; Miletic, H.; Sakariassen, P. O.; Stieber, D.; Rygh, C. B.; Lund- Johansen, M.; Zheng, L.; Gottlieb, E.; Niclou, S. P.; Bjerkvig, R. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol., 2014.
253. Hartwich, J.; Orr, W. S.; Ng, C. Y.; Spence, Y.; Morton, C.; Davidoff, A. M. HIF-1alpha activation mediates resistance to antiangiogenic therapy in neuroblastoma xenografts. J. Pediatr. Surg., 2013, 48(1), 39-46.
254. Xu, J.; Wang, J.; Xu, B.; Ge, H.; Zhou, X.; Fang, J. Y. Colorectal cancer cells refractory to anti-VEGF treatment are vulnerable to glycolytic blockade due to persistent impairment of mitochondria. Mol. Cancer Ther., 2013, 12(5), 717-24.
255. Hasan, M. R.; Ho, S. H.; Owen, D. A.; Tai, I. T. Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int. J. Cancer, 2011, 129(9), 2115-23.
256. Hu, Y. L.; DeLay, M.; Jahangiri, A.; Molinaro, A. M.; Rose, S. D.; Carbonell, W. S.; Aghi, M. K. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res., 2012, 72(7), 1773-83.
257. Favaro, E.; Bensaad, K.; Chong, M. G.; Tennant, D. A.; Ferguson, D. J.; Snell, C.; Steers, G.; Turley, H.; Li, J. L.; Gunther, U. L.; Buffa, F. M.; McIntyre, A.; Harris, A. L. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab., 2012, 16(6), 751-64.
258. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M. M.; Simons, J. W.; Semenza, G. L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 2000, 60(6), 1541-5.
259. Phillips, R. J.; Mestas, J.; Gharaee-Kermani, M.; Burdick, M. D.; Sica, A.; Belperio, J. A.; Keane, M. P.; Strieter, R. M. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J. Biol. Chem., 2005, 280(23), 22473-81.
260. Das, B.; Yeger, H.; Tsuchida, R.; Torkin, R.; Gee, M. F.; Thorner, P. S.; Shibuya, M.; Malkin, D.; Baruchel, S. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res., 2005, 65(16), 7267-75.
261. Nilsson, M. B.; Zage, P. E.; Zeng, L.; Xu, L.; Cascone, T.; Wu, H. K.; Saigal, B.; Zweidler-McKay, P. A.; Heymach, J. V. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene, 2010, 29(20), 2938-49.
262. Fiume, L.; Vettraino, M.; Manerba, M.; Di Stefano, G. Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. Pharmacol. Res., 2011, 63(4), 328-34.
263. Schulze, A.; Harris, A. L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature, 2012, 491(7424), 364-73.
264. DeBerardinis, R. J.; Lum, J. J.; Hatzivassiliou, G.; Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab., 2008, 7(1), 11-20.